FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310127706> ?p ?o ?g. }

• W4310127706 endingPage "7357" @default.
• W4310127706 startingPage "7356" @default.
• W4310127706 abstract "Introduction FA is the most common inherited bone marrow failure syndrome caused by a mutation in one of 23 genes involved in DNA repair; the disease manifests as hematologic abnormalities by age seven with near uniform bone marrow failure in adult patients. The gold standard therapy is bone marrow transplantation (BMT), which portends best outcomes when performed at a young age from Human Leukocyte Antigen (HLA)-matched sibling donors. However, due to the underlying pathophysiology of the disease, FA patients are especially sensitive to the chemoradiation conditioning regimens used with BMT, leading to high short-term morbidity and an increased long-term cancer risk. Due to these challenges of conventional BMT in FA, IUHCT is an attractive non-myeloablative and non-immunosuppressive option capable of inducing donor-specific tolerance when in utero testing has identified pathogenic FA mutations. Here we analyzed whether non-conditioned IUHCT confers fetal engraftment as a potential therapy in the FA mouse disease model. Methods Fanconi anemia type C homozygous mice (Fancc-/-) underwent IUHCT on gestation day 14 (E14) via vitelline vein injections of 1x107 T-cell depleted bone marrow cells from green fluorescent protein (GFP)-expressing congenic donor mice. Littermate wild-type mice served as controls. Donor cell engraftment in peripheral blood and bone marrow was assessed by flow cytometry. To confirm long-term donor HSC engraftment, we performed primary and secondary transplantation of an equivalent number of BM mononuclear cells from either Fancc -/- or wild-type mice that had undergone IUHCT. Statistical analysis was performed via Welch's t-test. P values <0.05 were considered statistically significant; for graphical purposes ***p<0.001; **p<0.002; *p<0.033; nonsignificant, ns. Results Fancc-/- homozygous mice had significantly higher donor GFP+ cell engraftment than wild-type controls at one, three, and six months post-transplantation (Figure 1). This higher engraftment was maintained across cell types in peripheral blood including CD3+ T cells (0.7% vs 3.4%), B220+ B cells (1.2% vs 6.9%), GR1+ granulocytes (1.7% vs 10.6%), and CD11B+ myeloid cells (1.9% vs 11.5%). Analysis of the bone marrow of these mice at 6 months post-transplant similarly showed a trend toward increased donor cell engraftment of progenitor cell populations including LSK, HSPC, LTHSC, STHSC, MPP2, MPP3, MPP4, CLP, CMP, GMP, and MEP cells in Fancc -/- recipients compared to wild-type mice. At all timepoints after primary and secondary transplants, recipient mice engrafted with BM mononuclear cells from prenatally transplanted Fancc -/- mice had higher peripheral blood GFP+ chimerism than those engrafted with BM mononuclear cells from prenatally transplanted wild-type mice (Figure 2). Conclusion Fancc-/- homozygous mice have higher sustained donor cell engraftment compared with wild-type littermates, indicating successful engraftment and possible early selection for wild-type donor cells in this preclinical model. These initial studies support the potential of IUHCT as a therapy for FA and highlight the need for additional studies to identify approaches to enhance donor cell engraftment to more clinically relevant levels. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310127706 created "2022-11-30" @default.
• W4310127706 creator A5005752595 @default.
• W4310127706 creator A5031326966 @default.
• W4310127706 creator A5051621145 @default.
• W4310127706 creator A5052969799 @default.
• W4310127706 creator A5056192441 @default.
• W4310127706 creator A5065648761 @default.
• W4310127706 creator A5075849774 @default.
• W4310127706 date "2022-11-15" @default.
• W4310127706 modified "2023-09-28" @default.
• W4310127706 title "Sustained Engraftment in Fanconi Anemia (FA) Mice Using <i>in Utero</i> Hematopoietic Cell Transplantation (IUHCT)" @default.
• W4310127706 doi "https://doi.org/10.1182/blood-2022-170456" @default.
• W4310127706 hasPublicationYear "2022" @default.
• W4310127706 type Work @default.
• W4310127706 citedByCount "0" @default.
• W4310127706 crossrefType "journal-article" @default.
• W4310127706 hasAuthorship W4310127706A5005752595 @default.
• W4310127706 hasAuthorship W4310127706A5031326966 @default.
• W4310127706 hasAuthorship W4310127706A5051621145 @default.
• W4310127706 hasAuthorship W4310127706A5052969799 @default.
• W4310127706 hasAuthorship W4310127706A5056192441 @default.
• W4310127706 hasAuthorship W4310127706A5065648761 @default.
• W4310127706 hasAuthorship W4310127706A5075849774 @default.
• W4310127706 hasBestOaLocation W43101277061 @default.
• W4310127706 hasConcept C109159458 @default.
• W4310127706 hasConcept C114538912 @default.
• W4310127706 hasConcept C126322002 @default.
• W4310127706 hasConcept C134935766 @default.
• W4310127706 hasConcept C172680121 @default.
• W4310127706 hasConcept C201614185 @default.
• W4310127706 hasConcept C203014093 @default.
• W4310127706 hasConcept C2777408962 @default.
• W4310127706 hasConcept C2778124228 @default.
• W4310127706 hasConcept C2779234561 @default.
• W4310127706 hasConcept C28328180 @default.
• W4310127706 hasConcept C2911091166 @default.
• W4310127706 hasConcept C2993713153 @default.
• W4310127706 hasConcept C502942594 @default.
• W4310127706 hasConcept C54355233 @default.
• W4310127706 hasConcept C552990157 @default.
• W4310127706 hasConcept C71924100 @default.
• W4310127706 hasConcept C86803240 @default.
• W4310127706 hasConceptScore W4310127706C109159458 @default.
• W4310127706 hasConceptScore W4310127706C114538912 @default.
• W4310127706 hasConceptScore W4310127706C126322002 @default.
• W4310127706 hasConceptScore W4310127706C134935766 @default.
• W4310127706 hasConceptScore W4310127706C172680121 @default.
• W4310127706 hasConceptScore W4310127706C201614185 @default.
• W4310127706 hasConceptScore W4310127706C203014093 @default.
• W4310127706 hasConceptScore W4310127706C2777408962 @default.
• W4310127706 hasConceptScore W4310127706C2778124228 @default.
• W4310127706 hasConceptScore W4310127706C2779234561 @default.
• W4310127706 hasConceptScore W4310127706C28328180 @default.
• W4310127706 hasConceptScore W4310127706C2911091166 @default.
• W4310127706 hasConceptScore W4310127706C2993713153 @default.
• W4310127706 hasConceptScore W4310127706C502942594 @default.
• W4310127706 hasConceptScore W4310127706C54355233 @default.
• W4310127706 hasConceptScore W4310127706C552990157 @default.
• W4310127706 hasConceptScore W4310127706C71924100 @default.
• W4310127706 hasConceptScore W4310127706C86803240 @default.
• W4310127706 hasIssue "Supplement 1" @default.
• W4310127706 hasLocation W43101277061 @default.
• W4310127706 hasOpenAccess W4310127706 @default.
• W4310127706 hasPrimaryLocation W43101277061 @default.
• W4310127706 hasRelatedWork W2031492102 @default.
• W4310127706 hasRelatedWork W2095958828 @default.
• W4310127706 hasRelatedWork W2126645487 @default.
• W4310127706 hasRelatedWork W2414647507 @default.
• W4310127706 hasRelatedWork W2415832748 @default.
• W4310127706 hasRelatedWork W2461245741 @default.
• W4310127706 hasRelatedWork W2555540422 @default.
• W4310127706 hasRelatedWork W2789319998 @default.
• W4310127706 hasRelatedWork W3000077724 @default.
• W4310127706 hasRelatedWork W4309388949 @default.
• W4310127706 hasVolume "140" @default.
• W4310127706 isParatext "false" @default.
• W4310127706 isRetracted "false" @default.
• W4310127706 workType "article" @default.